FDA approves Qfitlia to cut bleeding episodes in patients with hemophilia
The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce ...
EconoTimes17h
Aaron Humphrey
EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...
The Pharma Letter58m
CSL’s Hemgenix gene therapy gains German reimbursement
Australian biotech major CSL Limited (ASX: CSL) subsidiary CSL Behring today announced that it has successfully concluded ...
The Pharma Letter21h
NICE recommends Sobi’s Altuvoct for severe hemophilia A
Swedish Orphan Biovitrum, the Nordic biotech also known as Sobi, has announced that the National Institute for Health and ...
Indiatimes14h
Sanofi India Share Price
Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 13,460.48 Crore) operating in Pharmaceuticals sector. Sanofi India Ltd. key Products/Revenue Segments ...
Business Standard22h
Sanofi India Share Price
3 Year-23.11%-11.67% 34.42% 36.57% ...